Comparison of a new triazole antifungal agent, schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 2, 1999, Pages 322-328

  Connolly, Patricia ^a,b   Wheat, Joe ^a,b,c   Schnizlein Bick, Carol ^a   Durkin, Michelle ^a,b   Kohler, Steve ^b,c   Smedema, Melinda ^a,b   Goldberg, Janet ^a,b   Brizendine, Edward ^a   Loebenberg, David ^d  

^a Department of Medicine ^*  (United States)

^b Histoplasmosis Reference Laboratory   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ITRACONAZOLE; POSACONAZOLE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPLASMOSIS; IMMUNOCOMPETENCE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0032992658     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.2.322     Document Type: Article

References (25)

1. Bodet, C. A., III, J. H. Jorgensen, and D. J. Drutz. 1985. Simplified bioassay method for measurement of flucytosine or ketoconazole. J. Clin. Microbiol. 22:157-160.
2. Cacciapuoti, A., R. Parmegiani, D. Loebenberg, B. Antonacci, et al. 1995. Efficacy of SCH 56592 in pulmonary aspergillosis and candidiasis in mice, abstr. F66, p. 124. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
3. Clemons, K. V., and D. A. Stevens. 1995. Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis. Antimicrob. Agents Chemother. 39:778-780.
4. Conover, W. J., and R. L. Iman. 1981. Rank transformations as a bridge between parametric and nonparametric statistics. Am. Stat. 35:124-129.
5. Dismukes, W. E., R. W. Bradsher, Jr., G. C. Cloud, C. A. Kauffman, S. W. Chapman, R. B. George, D. A. Stevens, W. M. Girard, C. Bowles-Patton, and NIAID Mycoses Study Group. 1992. Itraconazole therapy for blastomycosis and histoplasmosis. Am. J. Med. 93:489-497.
6. Durkin, M. M., P. A. Connolly, and L. J. Wheat. 1997. Comparison of radioimmunoassay and enzyme-linked immunoassay methods for detection of Histoplasma capsulatum var. capsulatum antigen, J. Clin. Microbiol. 35: 2252-2255.
7. Fojtasek, M. F., M. R. Sherman, T. Garringer, R. Blair, L. J. Wheat, and C. T. Schnizlein-Bick. 1993. Local immunity in lung-associated lymph nodes in a murine model of pulmonary histoplasmosis. Infect. Immun. 61:4607-4614.
8. Hector, R. F., B. L. Zimmer, and D. Pappagianis. 1990. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob. Agents Chemother. 34:587-593.
9. Kobayashi, G. S., S. J. Travis, M. G. Rinaldi, and G. Medoff. 1990. In vitro and in vivo activities of SCH 39304, fluconazole, and amphotericin B against Histoplasma capsulatum. Antimicrob. Agents Chemother. 34:524-528.
10. Kohler, S., R. Blair, C. Schnizlein-Bick, M. Fojtasek, P. Connolly-Stringfield, and J. Wheat. 1194. Clearance of Histoplasma capsulatum variety capsulatum antigen is useful for monitoring treatment of experimental histoplasmosis. J. Clin. Lab. Anal. 8:1-3.
11. Laughlin, M., S. Pai, S. Menon, A. Nomeir, R. Colucci, M. Affrime, and T. Kosoglou. 1997. SCH 56592: rising multiple-dose safety, tolerance, and pharmacokinetic evaluation in healthy volunteers, abstr. A87, p. 18. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Lutz, J. E., K. V. Clemons, B. H. Aristizabal, and D. A. Stevens. 1997. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. 41:1558-1561.
13. Nomeir, A., P. Kumari, M. J. Hilbert, D. Loebenberg, et al. 1995. Comparative pharmacokinetics of a new triazole antifungal agent SCH 56592, in mice, rats, rabbits, dogs and cynomolgus monkeys, abstr. F68, p. 124. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Pappagianis, D., B. L. Zimmer, G. Theodoropoulos, M. Plempel, and R. F. Hector. 1990. Therapeutic effect of the triazole bay R 3783 in mouse models of coccidioidomycosis, blastomycosis, and histoplasmosis. Antimicrob. Agents Chemother. 34:1132-1138.
15. Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell. 1996. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40:1910-1913.
16. Smedema, M., P. Connolly, and J. Wheat. 1996. Antifungal susceptibility testing on isolates of Histoplasma capsulatum obtained from a clinical trial evaluating fluconazole treatment in patients with AIDS, abstr. F65, p. 85. In Abstracts of the 96th General Meeting of the American Society for Microbiology, 1996. American Society for Microbiology. Washington, D.C.
17. Stein, A. G., T. K. Daneshmend, D. W. Warnock, N. Bhaskar, J. Burke, and C. J. Hawkey. 1989. The effects of H2-receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. Br. J. Clin. Pharmacol. 27:105P-106P.
18. Sugar, A. M., and X. P. Liu. 1996. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. 40:1314-1316.
19. Tucker, R. M., D. W. Denning, L. H. Hanson, M. G. Rinaldi, J. R. Graybill, P. K. Sharkey, D. Pappagianis, and D. A. Stevens. 1992. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin. Infect. Dis. 14:165-174.
20. Waitz, J. A., M. S. Bartlett, M. A. Ghannoum, A. Espinel-Ingroff, M. V. Lancaster, F. C. Odds, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, T. J. Walsh, and J. N. Galgiani. 1997. Reference method of broth dilution antifungal susceptibility testing of yeasts; approved standard, p. 1-29. Report M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Wheat, J., R. Hafner, A. H. Korzun, M. T. Limjoco, P. Spencer, R. A. Larsen, F. M. Hecht, W. Powderly, and AIDS Clinical Trial Group. 1995. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am. J. Med. 98:336-342.
22. Wheat, J., R. Hafner, M. Wulfson, P. Spencer, K. Squires, W. Powderly, B. Wong, M. Rinaldi, M. Saag, R. Hamill, R. Murphy, P. Connolly-Stringfield, N. Briggs, S. Owens, and NIAID Clinical Trials and Mycoses Study Group Collaborators. 1993. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 118:610-616.
23. Wheat, J., P. Marichal, H. Vanden Bossche, A. Le Monte, and P. Connolly. 1997. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob. Agents Chemother. 41:410-414.
24. Wheat, J., S. Mawhinney, R. Hafner, D. McKinsey, D. F. Chen, A. Korzun, K. J. Shakan, P. Johnson, R. Hamill, D. Bamberger, P. Pappas, J. Stansell, S. Koletar, K. Squires, R. A. Larsen, T. Cheung, N. Hyslop, K. K. Lai, D. Schneider, C. Kauffman, M. Saag, W. Dismukes, and W. Powderly. 1997. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am. J. Med. 103:223-232.
25. Worsham, P. L., and W. E. Goldman. 1988. Quantitative plating of Histoplasma capsulatum without addition of conditioned medium or siderophores. J. Med. Vet. Mycol. 26:137-143.